OPKO Health (NASDAQ:OPK): Q1 2026 Earnings Preview and Financial Health Analysis

Font: Financial Modeling Prep  • Apr 28, 2026

• OPKO Health, Inc. (NASDAQ:OPK), a biopharmaceutical and diagnostics company with a market capitalization of $926.10 million, is set to report its Q1 2026 financial results.
• Wall Street analysts project Q1 2026 revenue of approximately $130.51 million and an earnings per share (EPS) estimate of -$0.07, indicating an expected net loss.
• Despite current unprofitability (negative P/E ratio of -4.10), OPKO Health demonstrates strong liquidity with a current ratio of 3.97 and a manageable debt-to-equity ratio of 0.34.

OPKO Health, Inc. (NASDAQ:OPK) is a leading biopharmaceutical and diagnostics company with a market capitalization of $926.10 million. This innovative company specializes in developing and commercializing new drugs and medical tests. Investors are keenly awaiting its first-quarter 2026 financial results, scheduled for release on April 28, 2026, after the U.S. financial markets close.

For the upcoming quarter, Wall Street analysts project OPKO Health's revenue to be approximately $130.51 million. They also anticipate an earnings per share (EPS) estimate of -$0.07. This EPS figure, which represents the profit a company makes for each share of its stock, indicates an expected net loss for the period, a key point for investor analysis.

As highlighted by Zacks Investment Research, OPKO Health's revenue streams are significantly supported by its proprietary drug RAYALDEE and strategic pharmaceutical partnerships. The company benefits from a profit-sharing agreement with Pfizer for NGENLA and receives royalties from Lilly. However, a substantial reliance on RAYALDEE presents a notable concern, primarily due to ongoing pricing pressures and intense market competition within the sector.

OPKO Health's recent financial performance indicates a period of unprofitability, reflected in a negative price-to-earnings (P/E) ratio of -4.10. A negative P/E ratio typically arises when a company has reported a net loss over the past year. This trend is further corroborated by its negative earnings yield of -24.37%, a metric that assesses earnings relative to the share price and is crucial for stock valuation.

Despite its current unprofitability, OPKO Health demonstrates a degree of financial stability through its manageable debt-to-equity ratio of 0.34. This ratio indicates that the company has relatively less debt compared to its shareholder equity. Furthermore, OPKO Health's ability to cover short-term debts appears robust, evidenced by a strong current ratio of 3.97. A current ratio significantly above one typically suggests that a company is well-positioned to meet its immediate financial obligations.